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Glucocorticoids interfere with mycophenolate mofetil bioavail- to an immunosuppressive regimen consisting of cyclo-
ability in kidney transplantation. sporine (CsA) and prednisone significantly reduced the
Background. Steroids have been shown to induce the he- rate of acute rejection during the first 12 months afterpatic glucuronyltransferase (GT) expression enhancing the ac-
transplantation as compared to azathioprine- or placebo-tivity of uridine diphosphate-GT, the enzyme responsible for
treated patients [1–3]. Since then, MMF has been widelymycophenolic acid (MPA) metabolism. The impact of steroids
on MPA pharmacokinetics, however, has not been investigated used in a fixed daily dose of 2 g, in two divided adminis-
to date. trations, as adjunctive therapy in combination with a cal-
Methods. As a part of a steroid-sparing clinical trial, we cineurin inhibitor, CsA or tacrolimus, and steroids. Recentstudied the effect of steroids on MPA bioavailability in 26 kid-
evidence, however, suggests that a fixed dose regimenney transplant recipients.
Results. Despite that the MMF dose did not change signifi- of MMF no longer might be the best approach for the
cantly with time, dose-normalized MPA AUC0-12h was lower dur- management of transplant patients, and drug pharmaco-
ing the first month (triple therapy, high doses of steroids) than kinetic monitoring is advised [4–8].at month 6 post-surgery (triple therapy, low maintenance dose
Following oral administration MMF is rapidly absorbedof steroids (32.94  10.98 vs. 50.87  22.37 g/mL · h; P 
and hydrolyzed to the active compound mycophenolic0.01). During the steroid tapering and withdrawal phase (from
month 6 to 21 post-Tx), plasma MPA trough and peak concen- acid (MPA) throughout non-specific intestinal esterases
tration as well as AUC0-12h progressively increased, while plasma [9]. MPA is then converted to inactive metabolites by
MPA clearance and MPAG (the major MPA metabolite) glucuronidation mediated by the human uridine diphos-trough levels declined. Renal function was stable throughout.
phate glucuronosyltransferase (UDP-GT) enzyme familySince cyclosporine A (CsA) may interfere with MPA pharma-
cokinetics, MPA and CsA also were measured in an additional [9]. The main metabolite, 7-hydroxy-glucuronide (MPAG),
control group of 12 kidney transplant patients at month 21 post- is excreted in urine but may contribute to the enterohep-
Tx who were still on triple therapy (MMF, CsA and steroids). atic circulation of MPA after excretion into the bile andDespite a similar CsA exposure, the control group had a sig-
hydrolysis in the gastrointestinal tract [10]. Recent re-nificantly lower MPA AUC0-12h and higher MPAG trough con-
ports also demonstrate that at least two acyl glucuronidescentration than patients on dual therapy at month 21 post-Tx.
Conclusion. These findings indicate that steroids interfere of MPA can be detected in the blood and formed in
with MPA bioavailability, and that discontinuation of the drug vitro [11].
results in higher MPA exposure, which may compensate at least Modulation of MPA metabolism by concomitant ad-in part for the lower immunosuppressive level achieved with
ministration of drugs other than MMF therefore maythe remaining dual therapy with CsA and MMF.
result in the modification of MPA clearance and eventu-
ally bioavailability. Previous studies in transplant recipi-
ents indeed have shown that CsA influences MPA phar-Three large double-blind, randomized trials in kidney
transplant recipients have shown that the addition of the macokinetics to the extent that a significant difference
novel antirejection drug, mycophenolate mofetil (MMF), was found in the MPA trough level between CsA versus
non-CsA treated patients, despite the fact that they were
treated with an identical MMF dose [12]. Changes inKey words: MPA pharmacokinetics, steroid withdrawal, kidney trans-
plantation, CsA pharmacokinetics, immunosuppression. MPA exposure may be biologically and clinically rele-
vant, as indicated by increasing evidence of a causalReceived for publication December 4, 2001
relationship between MPA pharmacokinetics and acuteand in revised form March 13, 2002
Accepted for publication April 22, 2002 rejection [4–8] or the incidence of MPA-related side
effects [13, 14]. 2002 by the International Society of Nephrology
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Glucocorticoids have been reported to induce gluc- were on triple immunosuppressive therapy with CsA,
MP (8 mg/day) and MMF. All patients started with theuronosyltransferase expression, enhancing the activity
of UDP-GT in rat hepatocyte cells in culture and in vivo conventional 2 g/day MMF dose, in two divided adminis-
trations. Ten of them, however, required a MMF dose re-in rodent animal models [15]. Both UDP-GT 1A and 2B
isoforms are up-regulated by dexamethasone in a dose- duction within the first 6 months post-transplant due to
adverse events. Changes in MMF dosing was performedand time-dependent manner [16]. Moreover, a preco-
cious development of UDP-GT activity occurred in fetal by the attending physicians based on clinical parameters
suggesting drug-induced toxicity, but not on MPA pharma-rats after glucocorticoid administration to the mothers
[17]. All together these observations led us to hypothe- cokinetics. Thereafter, the MMF daily dose remained fixed,
ranging from 500 mg to 2 g/day according to patient needs.size that glucocorticoids, by modulating UDP-GT activ-
ity could interfere with MPA metabolism in transplant At 6 months post-transplant, patients were allowed to
enter the steroid-sparing phase if the following inclusionpatients given steroids and MMF as a part of their immu-
nosuppressive therapy. The theoretical impact of ste- criteria were met: serum creatinine 2.0 mg/dL; stable
renal function in the last three months; proteinuriaroids on MPA pharmacokinetics, however, has not been
investigated so far. 1 g/day; and no more than two acute rejection episodes
in the first 6 months; no previous steroid-resistant acuteThe current study—which is a part of a multicenter
clinical trial aimed at investigating the steroid-sparing po- rejection episodes.
The study was described in detail to all patients be-tential of a MMF-based regimen in kidney transplants—
focused on two areas. We (1) compared the MPA phar- fore admission and informed consent obtained in each
instance.macokinetic profiles in the early post-transplant period
(within the first month), when patients were given rela-
Study designtively high dose steroids, with those in the later phase
(6 months post-transplant) under a lower maintenance This prospective study first examined the effect of
steroids on MPA pharmacokinetic profiles by comparingcorticosteroid regimen, when the patients received a
fixed daily dose of MMF; and (2) examined the effects kinetic parameters early post-transplant (within the first
month), when patients were given relatively high doseof steroid withdrawal on MPA bioavailability in the same
kidney transplant patients by comparing MPA pharma- of steroids, with those at 6 months post-surgery under
a lower maintenance steroid dosage, but still on triplecokinetics at six months post-surgery (while on MMF,
steroids and CsA), at the end of the steroid tapering immunosuppressive drug regimen (Fig. 1). The impact
of steroid withdrawal on MPA bioavailability in the samephase (9 months post-transplant), and at follow-up (21
months post-transplant). patients was assessed by evaluating MPA pharmacoki-
netic parameters and MPAG trough concentration at
different time points, namely at month 9 (end of steroid
METHODS
tapering phase) and month 21 (end of follow-up) post-
Patients transplant (Fig. 1). As a control for this second phase of
the study, an additional group of 12 kidney transplantTwenty-six consecutive adult renal transplant patients
(15 males, 11 females), enrolled as a part of a clinical trial recipients also were monitored at month 21 post-trans-
plant, when they were still on triple-drug therapy withaimed at investigating the steroid sparing potential of a
MMF-based immunosuppressive regimen, were included CsA, steroids, and MMF.
Moreover, in a subgroup of 12 study patients the per-in the present study. All were recipients of first kidney
transplant from cadaver donors, and aging from 19 to 61 centage of free MPA at time 0, in addition to the total
MPA trough level, was determined within the first monthyears. They were on triple-drug immunosuppressive regi-
men consisting of CsA (Neoral; Novartis, Basel, Switzer- and at 6, 9 and 21 months post-transplant.
On the morning of the pharmacokinetic studies, bloodland), methylprednisolone and MMF during the first six
months. In this period CsA dosing was established on samples were collected for routine biochemical analysis
and for the determination of trough levels of plasmathe basis of blood CsA trough levels targeted to 250 to
440 ng/mL, 200 to 300 ng/mL, and 150 to 250 ng/mL from MPA, MPAG and blood CsA. Each patient was then
given the morning dose of MMF and CsA and underwentdays 0 to 7, days 8 to 30, and months 2 to 6 post-trans-
plant, respectively. After intra-operative infusion of 500 an evaluation of simplified pharmacokinetic profiles. For
MPA pharmacokinetics, blood samples in EDTA-tubesmg methylprednisolone (MP), steroid dosing was then
progressively tapered to 16 mg/day up to day 12 post- were drawn at 20, 40, 75 and 120 minutes [4]. Thereafter,
samples were centrifuged at 3000 g, plasma separated,transplant, with maintenance 8 mg/day dose achieved
by 4 months post-surgery and maintained for 2 months and stored at20C until analysis by high-pressure liquid
chromatography (HPLC). For CsA pharmacokinetics,(month 6). MP was then progressively tapered over 90
days, and then withdrawn. Patients in the control group blood samples were collected in heparinized tubes at 60
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Fig. 1. Study design of the mycophenolic acid
(MPA) pharmacokinetic evaluation during the
early post-transplant (Tx) period (high dose
steroids), at month 6 (low maintenance steroid
dosage), at month 9 (end of tapering steroids),
and at month 21 post-Tx (1 year after steroid
withdrawal) in 26 kidney allograft recipients.
A control group of 12 kidney transplant patients
on triple immunosuppressive therapy at month
21 post-Tx was also studied. Symbols are: ()
MPA, cyclosporine A (CsA) pharmacokinet-
ics, mycophenolic acid metabolite (MPAG)
trough concentration; () evaluation of the
percentage of free MPA in a subgroup of 12
patients.
and 180 minutes after dosing [18] and stored at 20C The area under the time concentration (AUC) curve
from 0 to 2 hours (AUC0-2h) of MPA was calculated usinguntil analysis.
the linear trapezoidal rule. The extrapolated AUC0-12h
Plasma MPA and MPAG concentration measurement was estimated using the equation of Hale et al [4], which
is derived from more than 450 complete pharmacokineticTotal MPA and MPAG plasma concentrations were
measured by reverse phase high-performance liquid chro- profiles. The apparent clearance of MPA was calculated
as the ratio between MMF dose and MPA AUC0-12h.matography (HPLC), as previously described [19–21].
Briefly, plasma (500L) was added with 1.5 mL of water,
CsA blood concentration measurement50 L of internal standard solution (p-toluic acid; Sigma,
St. Louis, MO, USA) and 750 L of 0.1 N HCl. The The blood CsA concentration was determined by re-
verse-phase HPLC as previously described [23]. Briefly,mixture was applied to a C18 solid phase extraction col-
umn pre-conditioned with 2 mL of methanol followed peripheral vein blood samples were combined with HCl,
washed with heptane and extracted with diethyl ether.by 2 mL of water. The column was dried and then eluted
with 1 mL of methanol/0.1 N acetate buffer (80:20 vol/ The organic layer was then decanted, washed with sodium
hydroxide and evaporated to dryness. The residue wasvol) pH 4. Samples were collected in HPLC vials. The
mobile phase for elution of the column was 45% acetoni- reconstituted in 200 L of eluent and washed with hep-
tane; 50 L of aqueous layer were injected into a C-8trile and 55% aqueous phosphoric acid, at flow rate of
0.8 mL/min. The UV detector was set at 254 nm. HPLC column. Isocratic liquid chromatography separa-
tion was carried out using a mobile phase of acetoni-To estimate the plasma concentration of MPAG, a
glucuronidase solution (950 L) was added to 50 L of trile:methanol:water:ammonium sulfate at proportions
of 380:340:280:1. Trough level of blood CsA was deter-plasma. The mixture was incubated for one hour at 37C
and then processed for extraction as described above mined and the area under the time equals zero to 12 hours
post-dosing (AUC0-12h) was calculated from the AUC0-3h[20, 21]. MPAG was enzymatically hydrolyzed to MPA.
By subtracting the MPA concentration from total con- as previously described [18].
centration, MPAG concentration was estimated.
Statistical analysisFor free MPA determination the Centifree Micropar-
tition System (Amicon Millipore, Bedford, MA, USA) Results are reported as means  SD. Data were ana-
lyzed with paired and unpaired t test. Correlation be-was used [20, 22]. For the ultrafiltration procedure, 800 L
of plasma was added to the sample reservoir and the tween CsA AUC0-12h and plasma MPA clearance was
tube centrifuged at 5500 rpm (at 20C) for 40 minutes, performed by regression analysis. The statistical signifi-
yielding approximately 350 L of ultrafiltrate; this was cance level was defined as P  0.05.
mixed with internal standard p-toluic acid, and 100 L
of solution was then injected directly into the C18 col-
RESULTS
umn. The mobile phase consisted of solution A (250 mL
MPA and MPAG pharmacokinetics in the earlyacetonitrile and 300 mL of 20 mmol/L phosphate buffer,
post-transplant periodpH 3.0) and solution B (700 mL of acetonitrile and
300 mL of 20 mmol/L phosphate buffer, pH 6.5), eluted The mean MMF dose was numerically but not signifi-
cantly higher within the first month than at six monthswith a gradient from 3% B to 100% B in nine minutes,
at flow rate of 1.2 mL/min. Compounds were quantified post-transplant (1846  375 vs. 1596  530 mg/day).
Dose-normalized MPA trough levels in the first monthby absorbance at 215 nm.
Trough and maximum levels of MPA were determined. post-transplant tended to be higher than six month post-
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Fig. 2. Area under the curve (AUC; A) and
plasma clearance (B) of MPA within the first
month after transplantation (while patients
were on high dose steroids) and at 6 months
post-transplant (when they were under a lower
maintenance steroid regimen) in 26 kidney
graft recipients on triple immunosuppression
with MMF, CsA and steroids. *P  0.01 vs.
first month post-surgery.
Table 1. MMF dose and dose-normalized MPA pharmacokinetic parameters
Ct MPA Cmax MPAMMF dose AUC0–12h MPA
Time post-Tx mg/day lg/mL/g MMF lg/mL · h/g MMF
6th month 1596530 2.001.26 17.1610.91 50.8722.37
9th month 1500598 2.151.52 16.789.47 54.9124.17
21st month 1500559 3.132.35c 20.498.77d 66.6630.92ab
21st month (Controls) 1458582 1.640.77 15.235.06 45.5113.66
Values are mean  SD. Abbreviations are: MPA, mycophenolic acid; Ct MPA, plasma MPA concentration pre-dosing; Cmax MPA, maximum plasma MPA
concentration achieved after MMF dosing; AUC, estimated area under the time concentration curve from 0 to 12 hours post-MMF dosing.
a P  0.05 vs. month 6
b P  0.01 vs. controls
c P  0.05 vs. controls
d P  0.05 vs. month 6, 9, and controls
Tx values, but the difference did not reach statistical Dose-normalized MPA trough level progressively in-
significance (1.37 0.62 vs. 2.00 1.26 g/mL). By con- creased from month 6 (triple therapy) to month 9 (end
trast, a significantly lower dose-normalized maximum tapering) and month 21 (dual therapy) post-transplant.
plasma MPA concentration in the first month as com- The latter MPA trough level value was significantly
pared to six months post-transplant was found (7.34  higher (P  0.05) than that measured at the same time
5.47 vs. 17.16  10.01 g/mL; P  0.05). Similarly, as point post-surgery in control patients who were still on
shown in Figure 2A, dose-normalized MPA AUC0-12h was triple therapy with CsA, steroids and MMF. Dose-nor-
lower at one than six months post-surgery, with values malized peak MPA concentration also tended to increase
achieving statistically significant difference (32.94  with time as compared to month 6 values. Therefore, at
10.98 vs. 50.87  22.37 g/mL · h; P  0.01). Inversely the end of follow-up (month 21), peak MPA levels were
to change in AUC, mean apparent plasma clearance of significantly higher (P  0.05) than at months 6 and 9
MPA was significantly higher in the first month than at post-transplant. In patients who discontinued steroids,
six months post-transplant (P  0.01, Fig. 2B). When higher (P  0.05) peak MPA levels than in controls on
absolute, non-normalized values of MPA trough, maxi- triple drug therapy at month 21 post-surgery also were
mum plasma concentration and AUC were considered, found. Similarly, normalized MPA AUC0-12h progressivelysimilar results were found.
increased, reaching statistical significance (P  0.05) atBy contrast, MPAG trough levels were significantly
month 21 as compared to month 6 post-transplant. Thehigher in the first month as compared to month six post-
difference in MPA AUC0-12h values were even more sig-transplant values (50.72 34.06 vs. 33.28 14.22g/mL;
nificant (P  0.01) when patients who discontinued ste-P  0.05).
roids and controls were compared. Apparent plasma clear-In the subgroup of patients, in whom the percentage
ance of MPA showed progressive and significant declineof free MPA also was measured, higher values in the
(P  0.01) up to month 21 post-transplant in patientsfirst month as compared to six months post-surgery were
with steroid withdrawal (Fig. 3). A statistically significantfound (5.98  1.63 vs. 2.23  0.59%, P  0.01).
difference in plasma MPA clearance between steroid
MPA and MPAG pharmacokinetics after withdrawal and control groups also was documented
steroid withdrawal (P  0.01). Consistently, MPAG trough levels progres-
sively declined in patients who discontinued steroids,Table 1 summarizes the variation in MPA pharmaco-
reaching statistical significance at month 21 as comparedkinetic parameters at the end of tapering and after com-
plete steroid discontinuation. to month 6 post-transplant (24.30  11.43 vs. 33.28 
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Table 2. Impact of CsA pharmacokinetics on plasma MPA
clearance at month 6, 9, and 21 post-transplant
CsA dose Ct CsA AUC0-12h CsA CLMPA
mg/12 h ng/mL ng/mL · h mL/min
6th month 14526 19152 53131150 398.4205.4
9th month 14231 19763 50931252 368.0157.5
21st month 12826 17871 4202869a 298.4120.9abc
21st month
(Controls) 12518 10635a 3536769a 402.9147.2
Values are mean SD. Abbreviations are: CsA, cyclosporine; Ct CsA, blood
CsA concentration pre-dosing; AUC, estimated area under the time concentra-
tion curve from 0 to 12 hours post-CsA dosing; CLMPA, apparent plasma clearance
of MPA.
a P  0.01 vs. month 6
b P  0.01 vs. month 21 (Controls)
c P  0.05 vs. month 9Fig. 3. Changes of plasma MPA clearance during tapering dose and
after steroid withdrawal starting at 6 months post-transplant. At month
6 post-Tx, patients were on a triple-drug regimen with CsA, steroids,
and MMF; month 9 post-Tx was the end of steroid tapering; and month
21 post-Tx marked one year after steroid withdrawal. #Control patients
in controls still on triple-drug regimen up to month 21still on triple immunosuppressive therapy at month 21 post-surgery
also were included. *P  0.01 vs. month 6 and controls; P  0.05 vs. post-transplant, and related them to changes in plasma
month 9. MPA clearance.
As reported in Table 2, there was a numerical reduc-
tion in CsA dose in patients who discontinued steroids
from months 6 to 21 post-surgery. This was paralleled by
a tendency to decline of CsA trough levels and AUC0-12h
values. Changes in CsA pharmacokinetic parameters were
associated with decrease in plasma MPA clearance (Ta-
ble 2). In control patients at month 21 post-transplant
both blood CsA trough and CsA AUC0-12h values were
even numerically lower than those in patients with ste-
roid withdrawal at the same time-points (Table 2). Nev-
ertheless, control patients on triple-drug therapy had a
significantly higher plasma MPA clearance than patients
on the dual-drug regimen at month 21 post-transplant
(Table 2). By regression analysis, no significant correla-
tion was found between CsA AUC0-12h and plasma MPA
Fig. 4. Change of plasma MPAG trough level during tapering and clearance values when data of the two groups of patients
after steroid withdrawal starting at 6 months post-transplant. #Control
were considered (r  0.012, P  0.914; Fig. 5).patients still on triple immunosuppressive therapy at month 21 post-
surgery. *P  0.05 vs. triple therapy at month 6 and vs. controls at
month 21 post-transplant. Biochemical and hematological parameters
Table 3 shows renal function as the serum creatinine
and serum urea concentrations as well as serum albumin
level—factors that could potentially affect MPA binding14.22 g/mL; P 0.05; Fig. 4). At this time point MPAG
and pharmacokinetics [22, 25]—in the study patients andtrough levels were significantly lower than in the control
controls. Serum concentrations of creatinine and ureagroup (36.43  17.65 g/mL; P  0.05).
did not change to a significant extent in patients whoDespite changes in these pharmacokinetic parameters
discontinued steroids during the follow-up period, andassociated with tapering and discontinuation of steroids,
mean values were comparable to those of controls atthe percentage of free MPA measured in the subgroup
month 21 post-transplant. Similarly, serum albumin con-of patients was comparable at the three observation time
centration remained stable and comparable in the twopoints (month 6, 2.23 0.59; month 9, 2.40 0.53; month
groups of patients.21, 2.51  0.34).
There was a progressive reduction of red and white
Impact of CsA on plasma MPA pharmacokinetics blood cell count in parallel with tapering and discontinu-
ation of steroids that was associated with the increasedSince lowering CsA exposure per se may be a factor
MPA exposure (Table 3). A significant correlation be-that affects MPA pharmacokinetics [12, 24], we mea-
tween MPA AUC0-12h and red blood cell count during thesured CsA pharmacokinetic parameters in the same pa-
tients undergoing steroid tapering and withdrawal, and study period was found also (r  0.33; P  0.01).
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eventually leading to a lower than expected exposure to
MPA. Induction of liver UDP-glucuronosyltransferase
by glucocorticoids also might enhance the production of
the main MPA metabolite, MPAG [10], which in turn
displaces MPA from the albumin binding sites increasing
the free plasma fraction of the compound [22]. This was
indeed what we have found in the present study, where
the MPAG concentration and percentage of free MPA
were almost twofold higher early post-transplant than at
six months when patients were on a low maintenance dose
of steroid. On the other hand, the high percentage of
free MPA might compensate for the overall lower MPA
bioavailability early post-transplant, which was expected
to translate in less MMF-induced immunosuppression.
While together these results are quite supportive of
the involvement of steroids in the metabolism of MPA,
Fig. 5. Regression analysis of the relationship between CsA daily expo- at this stage they are still indirect and not conclusive. We
sure (AUC0-12h) and plasma MPA clearance in study and control kidney therefore sought to examine the impact of steroid with-transplant patients. R  0.012; P  0.914. Symbols are: () patients
who discontinued steroids; () controls. drawal on MPA pharmacokinetic parameters in the same
kidney graft recipients starting at six months post-sur-
gery. Despite that the MMF dose was unchanged, the ap-
parent MPA plasma clearance and the MPAG trough lev-
DISCUSSION els progressively declined during the three-month steroid
Potential pharmacokinetic interactions between MPA tapering period, and further reduced after discontinua-
and other immunosuppressive agents may induce signifi- tion of the drug, resulting in higher MPA exposure. By
cant changes in MPA exposure with relevant clinical con- contrast, control patients, who were still on triple-drug
sequences in terms of efficacy and side effects. therapy including steroids at the end of follow-up, had
Here we found that in cadaveric kidney transplant significantly higher MPA plasma clearance and MPAG
recipients on immunosuppressive therapy with CsA, ste- trough values. All together, these findings confirm our
roids and fixed dose of MMF, plasma clearance of MPA initial observation that steroids affect MPA pharmaco-
was higher early post-surgery than at six months when kinetics.
patients were still on the triple-drug regimen. This trans- However, an additional confounding factor in the in-
lated into a lower MPA daily exposure within the first terpretation of our results derives from recently pub-
month post-transplant. lished observations that CsA also may interfere with MPA
The reasons for lower MPA exposure early post-trans- metabolism [12, 24]. Lowering CsA exposure, as it oc-
plant could be multifactorial. Poor gastrointestinal ab- curred in patients discontinuing steroids, is indeed a fac-
sorption of MMF in the perioperative phase may account tor that could have decreased the MPA plasma clearance
at least partially for these MPA pharmacokinetic differ- and then enhanced MPA bioavailability. To explore this
ences. This possibility is supported by the fact that the possibility we compared CsA and MPA bioavailability
maximum MPA concentration achieved in the plasma, in patients who underwent steroid withdrawal and in con-
which reflects the degree of drug absorption, was also lower trols still on standard immunosuppression with CsA, ste-
in the first month post-transplant than at six months. roid and MMF at 21 months post-transplant. Despite that
In addition, a potential effect of CsA on the MPAG the bioavailability of CsA was higher in patients who
enterohepatic circulation pathway cannot be excluded discontinued steroid than in the control group, MPA
[12, 24]. Different MPA levels could reflect differences plasma clearance was markedly lower in the former group.
in the rate of drug metabolism through modulation of the This indicates that the contribution of CsA to the ob-
glucuronosyl-transferase enzyme in the liver. In this re- served MPA pharmacokinetic changes in patients dis-
spect, in vitro evidence is available that glucocorticoids, continuing steroids was marginal, if any. Failure of CsA
which are usually given at high daily doses in the early to affect MPA metabolism also was supported by the
postoperative period as a part of the immunosuppressive lack of any correlation between patient exposure to CsA
therapy, enhance the activity of UDP-glucuronosyltrans- and MPA plasma clearance values considering the whole
ferase in adult rat hepatocytes in culture and in human patient and control population. These findings are at vari-
liver specimens [15–17]. These findings raise the possibil- ance with results of MPA monitoring in kidney transplant
ity that in our patients, high dose steroids given early recipients showing a highly significant difference in MPA
concentration between patients treated with or without apost-transplant activate pathways of MPA metabolism,
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Table 3. Biochemical and hematological parameters
Serum creatinine Serum urea
Serum albumin RBC WBC
Time post-Tx mg/dL g/dL 106/lL 103/lL
6th month 1.300.33 53.518.9 3.90.4 4.70.9 9.22.5
9th month 1.420.41 56.619.1 3.80.3 4.50.8 6.82.0
21st month 1.340.16 58.314.4 4.00.3 4.30.8a 6.91.1
21st month (Controls) 1.330.37 65.126.3 3.70.6 4.80.6 8.02.2
Values are mean  SD. Abbreviations are: RBC, red blood cell count; WBC, white blood cell count.
a P  0.05 vs. controls
CsA-based regimen [12, 24, 26]. It should be considered, vided by the remaining unchanged dual drug regimen,
while allowing patients to safely avoid the side effects ofhowever, that in the latter studies the influence of CsA
on MPA pharmacokinetics was documented through long-term steroid administration. Whether MPA pharma-
cokinetic changes induced by steroid withdrawal trans-comparison with a completely CsA-free regimen, whereas
our patients were still on CsA treatment. This is in line late to a lower risk of acute graft rejection than that re-
with other investigators in a comparative study on the ported in patients on conventional azathioprine-based
effect of conventional CsA or tacrolimus dose, who found therapy, who per the protocol are undergoing corticoste-
no evidence of an impact of CsA on the MPA trough roid discontinuation to avoid the long-term sequelae of
level [27, 28]. Thus, we speculate that CsA may interfere the treatment [31], is under investigation in a prospec-
with MPA pharmacokinetics only when significant varia- tively-designed multicenter clinical trial.
tions in the patient’s exposure to CsA occurs.
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